Rules for selling biotechnologies to investors
On a good biotechnological innovation, an investor can earn tens and hundreds of millions, and sometimes billions of dollars.
03.09.2012On a good biotechnological innovation, an investor can earn tens and hundreds of millions, and sometimes billions of dollars.
03.09.2012If you don't have millions for a new drug, you can try to combine two promising trends and offer additional IT services to the medical market. In Russia, this direction has been actively developing recently.
31.08.2012The development of innovations in Russia is on the right track, said Yuri Udaltsov, Director of Innovation Development at Rusnano.
29.08.2012The united life sciences cluster has a chance to become an example of the qualitative development of cluster initiatives in St. Petersburg.
27.08.2012Serial entrepreneur Alexander Dresen has formulated 15 rules that make it possible to go through the difficult path of a startup.
24.08.2012Today, simulators of five types are being produced – for ambulance crews and surgeons specializing in minimally invasive operations on vessels, abdominal organs, the genitourinary system, and the reproductive sphere. In principle, it is possible to create virtual simulators for 96 medical specialties.
21.08.2012In response to accusations of insufficient innovation, domestic business blames the fact that science is divorced from reality and works most often for itself. Scientists themselves partly agree with this. But there are changes in this area.
09.07.2012In general, these four reasons mean that Rusnano Corporation is run by not very honest people who are very far from the business that they are entrusted with and entrusted with. Having very vague ideas about him.
06.07.2012The state does not spare money for Skolkovo – until 2014 it will pump about 85 billion rubles there. This is without taking into account voluntary and compulsory deductions of state-owned companies – also by tens of billions. How is this money distributed?
05.07.2012The list of pilot development programs that can qualify for subsidies from the federal budget includes two St. Petersburg innovation sites: the radiation technology cluster (almost half of its projects relate to medicine and pharmacology) and pharmaceutical.
03.07.2012On June 27, 2012, the solemn ceremony of awarding the winners of the XI Competition of Russian Innovations and the VII Student competition "The best business plan of an innovative project" took place.
29.06.2012In 2011, the costs of creating new drugs of the top 10 global pharmaceutical companies in terms of R&D costs amounted to more than $ 70 billion. US$, which is slightly higher than the same indicator in 2010.
28.06.2012At the BIO International Convention, a collective exposition of leading Russian companies developing innovative projects in the field of biotechnology within the framework of the implementation of the Pharma 2020 strategy was presented.
26.06.2012The technopark in Russia is being created for the sake of the technopark itself, and the achievement of its goal – the catalyzation of innovations – is lost in the three pines of economic, organizational and political interests.
20.06.2012Three candidate HIV vaccines have successfully passed the first stage of clinical trials. Scientists have not been able to start the next stages at which the effectiveness of vaccines should be established for two years due to the termination of funding.
08.06.2012St. Petersburg is formally considered one of the most innovative cities in Russia. However, despite the serious financial injections of the last four years, the city cannot yet boast of any significant innovations.
22.05.2012The Biobusinessincubator will create corporate laboratories of cluster members, host the first startups, which will have to gain momentum by 2014 and become part of the biopharmaceutical corps.
18.05.2012Residents of the St. Petersburg special economic zone, created 5 years ago, still cannot take advantage of the preferences provided by a residence permit in it.
10.05.2012In order to put the domestic pharmaceutical industry on an innovative track, it is necessary not to create numerous venture funds and clusters, but to build the necessary infrastructure and introduce the right taxes and tariffs.
02.05.2012Andrey Ivashchenko, Chairman of the Board of Directors of the Himrar Group of Companies, believes that Russian companies should at least win their market by taking advantage of the competitive advantage that domestic legislation gives them.
28.04.2012You can write to the editor at:
vm@vechnayamolodost.ruThe editors of Eternal Youth are preparing a useful and interesting mailing list. You can get it if you leave your mail.